Structural and parameter uncertainty in Bayesian cost-effectiveness models.
Health economic decision models are subject to various forms of uncertainty, including uncertainty about the parameters of the model and about the model structure. These uncertainties can be handled within a Bayesian framework, which also allows evidence from previous studies to be combined with the data. As an example, we consider a Markov model for assessing the cost-effectiveness of implantable cardioverter defibrillators. Using Markov chain Monte Carlo posterior simulation, uncertainty about the parameters of the model is formally incorporated in the estimates of expected cost and effectiveness. We extend these methods to include uncertainty about the choice between plausible model structures. This is accounted for by averaging the posterior distributions from the competing models using weights that are derived from the pseudo-marginal-likelihood and the deviance information criterion, which are measures of expected predictive utility. We also show how these cost-effectiveness calculations can be performed efficiently in the widely used software WinBUGS.
Jackson
Christopher H
CH
Medical Research Council Biostatistics Unit Cambridge, UK.
Sharples
Linda D
LD
Thompson
Simon G
SG
Stat Med. 2006 Jun 15;25(11):1960-75
16220511
Lancet. 2002 Aug 31;360(9334):711-5
12241891
Biostatistics. 2008 Jul;9(3):523-39
18209015
Neural Comput. 2002 Oct;14(10):2439-68
12396570
Circulation. 2001 Mar 13;103(10):1416-21
11245646
Stat Med. 2003 Dec 15;22(23):3687-709
14652869
Value Health. 2009 Jul-Aug;12(5):739-49
19508655
J R Stat Soc Ser A Stat Soc. 2009 Apr;172(2):383-404
19381329
Stat Med. 1993 Apr 30;12(8):717-36
8516590
Circulation. 2000 Aug 15;102(7):748-54
10942742
Health Econ. 2004 Mar;13(3):203-26
14981647
J R Stat Soc Ser A Stat Soc. 2009 Jan;172(1):21-47
19381328
Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164
16904046
N Engl J Med. 1997 Nov 27;337(22):1576-83
9411221